期刊文献+

滤泡性淋巴瘤的治疗进展

下载PDF
导出
摘要 滤泡性淋巴瘤是非霍奇金淋巴瘤中第二常见的病理亚型。传统的治疗方法为放疗及化疗,早期患者有可能通过放疗治愈,但晚期患者很少有治愈的希望。随着新的治疗策略不断涌现,包括单克隆抗体、放射免疫治疗、苯达莫司汀、自体及异体造血干细胞移植、来那度胺、蛋白酶体抑制剂,患者的生存率得到明显的改善。本文作者就滤泡性淋巴瘤的治疗进展作一综述。
作者 钟凤鸾 柳金
出处 《深圳中西医结合杂志》 2010年第3期182-186,共5页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
  • 相关文献

参考文献21

  • 1Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project/J). J Clinoncol, 1998, 16:2780-2795.
  • 2Ghielmini M, Hsu Schmitz SF, Cogliatti SB,et al. Prolonged treatment with rituximab in patients with follicular Lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule [J]. Blood, 2004, 103:4416-4423.
  • 3Hiddemann W, Kneba M, Dreyling Met al. Frontline therapy with fituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group [J]. Blood, 2005, 106:3725-3732.
  • 4Marcus R, Imrie K, Belch A,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma [J]. Blood, 2005, 105:1417- 1423.
  • 5McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma [J]. Semin Oncol, 2000, 27:37-41.
  • 6Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG) [J]. Blood, 2004, 104:3064-3071.
  • 7Van Oers MH. Rituximab maintenance therapy., a step forward in follicular lymphoma [J]. Haematologica, 2007, 92(6):826-833.
  • 8Van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial [J]. Blood, 2006, 108(10):3295-3301.
  • 9Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) [J] . Blood, 2006, 108(13):4003 -4008.
  • 10Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of Yttrium 904abeled Ibritumomab Tiuxetan radioimmunotherapy versus Rimximab immunotherapy for patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma [J]. J Clin Onc, 2002, 20(10):2453-2463.

二级参考文献10

  • 1黄灵芝.硼替佐米有望成为治疗非霍奇金淋巴瘤新药[J].国外医学(药学分册),2006,33(5):382-383. 被引量:2
  • 2Paul G, Bart Barlogie, James Berenson, et al. Extended follow-up of a phase Ⅱ trial in relapsed, refractory multiple myeloma[J].Cancer,2006,106(6):1316-1319.
  • 3Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma[J]. Blood, 2007,109(7):2767-2772.
  • 4Zangari M, Barlogie B, Thertulien R, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival[J]. Chin Lymphoma, 2003,4 (1):32-35.
  • 5Fanucchi M P, Fossella F V, Belt R, et al. Randomized phase Ⅱ study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer [J]. J Clin Oncol,2006,24(31) :5025-5033.
  • 6Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia[J]. Cancer, 2007,109(11):2285-2290.
  • 7Kim S J, Kim J, Cho Y, et al. bortezomib, cyclophosphamide Combination chemotherapy with and dexamethasone may be effective for plasma cell leukemia[J]. Jpn J Clin Oncol, 2007, May 303 Epub ahead of print.
  • 8Yan H, Wang Y C, Li D, et al, Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta[J]. Leukemia, 2007, 21 (7) : 1488-1495.
  • 9Faderl S, Rai K, Gribben J, et al. Phase Ⅱ study of single-agent bortezomib for the treatment of patients with fludarabine- refractory B-cell chronic lymphocytic leukemia[J]. Cancer, 2006, 107(5) : 916-924.
  • 10Daming Shan,Jeffrey A. Ledbetter,Oliver W. Press. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells[J] 2000,Cancer Immunology, Immunotherapy(12):673~683

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部